5.87
-0.2399(-3.93%)
Currency In USD
| Previous Close | 6.11 |
| Open | 6 |
| Day High | 6.21 |
| Day Low | 5.87 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 5.87 |
| Volume | 4,348 |
| Average Volume | 139,385 |
| Market Cap | 3.42M |
| PE | 0 |
| EPS | -2,292.56 |
| Moving Average 50 Days | 7.75 |
| Moving Average 200 Days | 22.23 |
| Change | -0.24 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.01 as of November 20, 2025 at a share price of $5.87. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.15 as of November 20, 2025 at a share price of $5.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
GlobeNewswire Inc.
Nov 05, 2025 11:00 AM GMT
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
GlobeNewswire Inc.
Oct 22, 2025 10:00 AM GMT
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
GlobeNewswire Inc.
Oct 14, 2025 10:09 AM GMT
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of recor